Sage Journals: Discover world-class research

Abstract

Background:

Clostridium difficile infection (CDI) is treated most often with metronidazole or vancomycin. Both have been effective in treatment of mild to moderate infection. In more severe cases, vancomycin may be more effective.

Objectives:

The primary objectives were to quantify the severity of CDI and to describe overall adherence to the institutional CDI guideline. Secondary objectives were to assess factors associated with adherence to the guidelines.

Methods:

Retrospective analysis of the electronic medical record was used to evaluate adherence to institutional guidelines. Data collected included demographics and other factors potentially contributing to adherence: Charlson comorbidity index, severity of infection, recurrence, intensive care unit (ICU) admission, infectious diseases (ID) consult, total duration and number of antibiotics, alternative therapies, and acid suppression. Descriptive statistics and bivariate analyses were used to describe and compare factors associated with guideline adherence; multivariate logistic regression assessed independent predictors of adherence.

Results:

A total of 387 patients met the inclusion criteria. CDI severity was 55.8% mild/moderate cases, 42.4% severe, 0.5% fulminant, and 1.3% prophylaxis. Overall, institutional guideline adherence was 51.9%. In bivariate analyses, 5 factors were associated with nonadherence to guidelines: older age, ICU admission, duration of antibiotics, mild/moderate and severe infection (all P < .05). In the logistic regression model, severe infection (P < .001) and longer duration of antibiotics (P < .05) were independently associated with guideline nonadherence.

Conclusion:

In this study, 42.4% of the patients met criteria for severe infection. Providers for patients with severe infection and longer duration of antibiotic therapy were less likely to adhere to the institutional guideline.

Keywords

infectious diseases

Get full access to this article

View all access options for this article.

References

Hurley

Nguyen

. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med. 2002;162(19):2177–2184.

Hall

Curns

McDonald

. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012;55(2):216–223.

Loo

Poirier

Miller

. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–2449.

Pepin

Valiquette

Cossette

. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173(9):1037–1042.

Dubberke

Butler

Reske

. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis. 2008;14(7):1031–1038.

Lessa

Bamberg

. Burden of Clostridium difficile infection in the United States. New Eng J Med. 2015;372(9):825–834.

Cohen

Gerding

Johnson

. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.

Zar

Bakkanagari

Moorthi

. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–307.

Olson

Shanholtzer

Lee

Jr . Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994;15(6):371–381.

10.

Bartlett

. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis. 1984;(suppl 1): S235–S241.

11.

Bartlett

. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15(4):573–581.

12.

Louie

Miller

Mullane

. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431.

13.

Charlson

Pompei

Ales

. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.

14.

Charlson

Szatrowski

Peterson

. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.

15.

StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp L; 2011.

16.

Gerding

. Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents. 2009;33(suppl 1): S2–S8.

17.

McDonald

Killgore

Thompson

. An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med. 2005;353(23):2433–2441.

18.

Pépin

Valiquette

Alary

. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466–472.

19.

Chitnis

Holzbauer

Belflower

. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–1367.

20.

Pituch

. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents. 2009;33(suppl 1): S42–S45.

21.

Stevens

Nelson

Schwasb-Daugherty

. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection [published online February 6, 2017]. JAMA Intern Med. doi:10.1001/jamainternmed.2016.9045.

22.

Debast

Bauer

Kuijper

; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(suppl 2):1–26.

23.

Surawicz

Brandt

Binion

. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498; quiz 499.

A Retrospective Study of Patient Factors That Indicate Provider Nonadherence to an Institutional Clostridium difficile Treatment Guideline